The United States Patent Trial and Appeal Board has handed a win to Chinese-American synthetic biologist Feng Zhang (張鋒) and his team from the Massachusetts Institute of Technology (MIT) in a dispute over patents of the gene editing technology known as CRISPR.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Taiwan shares end down as tech sector hit by Fed worries
11/18/2024 05:21 PM - Society
Bus companies fined NT$90,000 for fatal collision in Taipei
11/18/2024 04:59 PM - Business
U.S. dollar closes higher on Taipei forex market
11/18/2024 04:31 PM - Business
Taiwan's Q3 IC output up 9% from Q2 on peak season effects: ITRI
11/18/2024 04:26 PM - Society
Life satisfaction of Taiwanese children drops to all-time low: Survey
11/18/2024 04:09 PM